These are the first studies to demonstrate the ability to halt the progression of fibrosis using IL-6 neutralizing antibodies suggesting IL-6 as a potential therapeutic target for treating pulmonary disorders where fibrosis is abundant. This evidence concerns the gene IL6 and lung disorder.